Sarah Yim, M.D.

Director, Office of Therapeutic Biologics and Biosimilars, Office of New Drugs (OND), CDER

Sarah Yim, M.D., is Director of the Office of Therapeutic Biologics and Biosimilars in CDER’s Office of New Drugs (OND), FDA. From 2017 to 2019, she spent two years as Director of the Division of Clinical Review in the Office of Generic Drugs, and 11 years before that in various roles in rheumatology drug review in OND. She received her undergraduate degree from Stanford University, her Doctor of Medicine degree from the Uniformed Services University of Health Sciences and completed a postdoctoral fellowship in rheumatology at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health.

Early bird tickets
available now